Unveiling a Revolutionary Approach: DNA-Based Scaffolding for HIV Vaccines
The Quest for an HIV Vaccine: A Complex Immune Puzzle
Developing an HIV vaccine is no ordinary task. Scientists face the challenge of guiding the body to produce specific immune cells and antibodies that can effectively combat the virus. Traditional vaccines often use larger protein scaffolds to mimic a virus, but this approach has its pitfalls.
The Breakthrough: DNA Scaffolding Ignites Hope
Researchers from Scripps Research and MIT have crafted a novel vaccine scaffolding made from DNA, a material that the immune system naturally ignores. In a recent study published in Science, they demonstrated that this DNA-based approach led to a remarkable tenfold increase in immune cells targeting a critical site on HIV compared to protein-based scaffolds. This suggests a more potent and precise immune response.
"This technology opens up new possibilities for not just an HIV vaccine but also for tackling other complex vaccine challenges," says Dr. Darrell Irvine, a professor at Scripps Research and senior author of the study.
Understanding the Traditional Vaccine Scaffold
A typical vaccine consists of a scaffolding particle adorned with numerous inert viral proteins (antigens) that the immune system can recognize. These vaccine structures, much like viruses, present multiple copies of an antigen on their surface, triggering a stronger immune response than free-floating antigens used in older, less effective vaccines. However, most of these scaffolds are made from proteins, which can provoke immune reactions against the scaffold itself.
The Challenge with Off-Target Immune Reactions
While off-target immune reactions may not be a significant issue for vaccines targeting common pathogens, they become critical for more complex targets like HIV, influenza, and pan-coronavirus vaccines. In these cases, broadly protective B cells are exceptionally rare, and every competing immune response can impact the vaccine's effectiveness.
"We knew protein nanoparticle scaffolds generated their own immune responses, but the extent to which these off-target responses limited the desired immune cells was unclear," explains Irvine, who is also an Investigator at the Howard Hughes Medical Institute.
DNA Origami: A Silent Immunological Approach
In their new work, Irvine and his team, led by Anna Romanov, turned to DNA origami technology. This innovative technique allows scientists to fold DNA into precise three-dimensional shapes. The researchers chose DNA origami because B cells, the immune cells responsible for recognizing antigens and producing antibodies, do not flag DNA. This is a natural protective mechanism to prevent autoimmune reactions.
Mark Bathe, a biological engineer at MIT and a collaborator on the project, elaborates, "In our prior work using a SARS-CoV-2 antigen, we found DNA scaffolds were 'silent' immunologically, not generating an antibody response. This study now demonstrates that DNA scaffolds can promote focused germinal center responses, a breakthrough for active immunotherapy.
The DNA-Based Vaccine: A Focused Immune Response
The team designed DNA nanoparticles that could display 60 copies of an HIV envelope protein, known to activate the rare B cells that can produce broadly neutralizing antibodies against HIV. When tested in mice expressing human antibody genes, nearly 60% of the germinal center B cells targeted the HIV envelope protein. In contrast, the protein-scaffolded vaccine, currently in clinical trials, generated germinal centers where only about 20% of B cells recognized the HIV target, with many cells responding to the scaffold itself.
The DNA-based vaccine achieved a remarkable 25-fold better ratio of HIV-specific to off-target immune cells compared to the protein scaffold. Within two weeks of vaccination, mice receiving the DNA-based vaccine had detectable levels of the desired rare B cells, while mice receiving the protein nanoparticle-based vaccine had none.
Implications Beyond HIV
The implications of this study extend beyond HIV. The same challenges apply to developing universal influenza and pan-coronavirus vaccines. DNA origami scaffolds could provide a more focused immune response for these complex vaccine problems, says Irvine.
"These vaccines aim to recruit incredibly rare cells in the B-cell repertoire. Anything that limits the activation of these correct cells is a potential hurdle, and DNA origami scaffolds offer a promising solution to overcome these challenges," he adds.
The Irvine and Bathe teams are now delving deeper into the impact of variations in DNA origami shape on vaccine effectiveness and assessing the long-term safety of these scaffolds for vaccination.
Reference
Romanov A, Knappe GA, Ronsard L, et al. DNA origami vaccines program antigen-focused germinal centers. Sci. 2026;391(6785):eadx6291. doi:10.1126/science.adx6291
